Zenas Raises $200m For Bifunctional Antibody In Autoimmune Diseases

Obexelimab Is In Phase III In IgG4-Related Disease

 
• By Mandy Jackson

Zenas BioPharma plans to have data from four trials – two under way and two starting this summer – for obexelimab, which targets CD19 and FcγRIIb, within about a year and a half.

Investors. Shareholders, co-owners. Startups and fundraising.
Zenas will increase its headcount by 20% • Source: Shutterstock

More from Financing

More from Business